ClinicalTrials.gg
RecruitingNCT05780450Updated Oct 15, 2026

Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.

An interventional study of Transcranial Direct Current Therapy (tDCS) and Sham (No Treatment) in COVID-19, Long COVID and Long Covid19, sponsored by Fundación Universidad Católica de Valencia San Vicente Mártir. Recruiting at 2 sites in Spain. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionPost-Acute COVID-19 SyndromeRegistry: COVID-19ReclassifiedWhy we changed it
Registry
COVID-19 — the first condition term the registry derived for this study.
ClinicalTrials.gg
Post-Acute COVID-19 Syndrome
Why
  1. The study's listed conditions name Post-Acute COVID-19 Syndrome, a narrower term within COVID-19.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fundación Universidad Católica de Valencia San Vicente Mártir · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.
Updated Oct 15, 2026Now RecruitingPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Spain.

Planned enrollment
14th of 39
87 · median 60
Started
2023
with 11 others
No phase
31 of 52
7 open now
Primary completion
2026-11
later than 10 of 15 live
Registered
21st of 52
by date

Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, this one is the 14th largest by planned enrollment of the 39 interventional ones that give a count, is one of 12 that started in 2023, is one of 31 with no phase, reaches primary completion later than 10 of the 15 other live ones, and was the 21st registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

13 of the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, or all of them as a file.
02

Study summary

This study aims to verify the efficacy/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and myalgia, as well as sleep problems. Transcranial direct current stimulation is used in the field of Physiotherapy and Rehabilitation, with results that have proven to be effective for treating patients suffering from symptoms like migraines, headaches, chronic pain, fibromyalgia, or chronic neuropathic pain and insomnia. As you can see, in the case of patients with Long Covid, we find several of these symptoms, so it is suggested that if transcranial direct current therapy (TDCS) gives such good results in relieving these symptoms, why couldn't it give such good results and help just as much in patients with Long Covid, since many of the symptoms are the same, even if the origin or cause is different.

Read the detailed description

Study extension (amendment to protocol UCV/2021-2022/140, approved by the Research Ethics Committee of the Catholic University of Valencia, ref. UCV/2022-2023/072, on October 28, 2024). After the initial phase, in which participants with Long COVID received anodal tDCS, the study was extended to a randomized, sham-controlled, double-blind phase. Participants are randomized 1:1:1:1 to anodal (original arm, recruitment continued), bifrontal, cathodal or sham tDCS. Objectives, eligibility criteria and primary outcome are unchanged. Planned enrollment: initial phase, 27 participants; randomized extension phase, 60 participants (15 per arm). Between-group comparisons will include only participants randomized in the extension phase; initial-phase data will be reported separately and used only in supplementary analyses within the anodal tDCS arm. Sleep outcomes (PSQI, ISI, ESS) were added as secondary outcomes in the extension phase only.

The initial phase was approved by the Research Ethics Committee of the Catholic University of Valencia (ref. UCV/2021/2022/140); the extension was approved by the Research Ethics Committee of the Catholic University of Valencia (ref. UCV/2022-2023/072) on October 28, 2024.

03

Conditions studied

  • COVID-19
  • Long COVID
  • Long Covid19
  • SARS CoV 2 Infection
  • Persistent COVID-19
  • Migraine Disorders
  • Headaches Chronic
  • Cluster Headache
  • Arthralgia
  • Myalgia
  • Chronic Pain
  • Post-COVID-19 Syndrome
  • Post COVID-19 Condition
  • Sleep Quality
  • Insomnia

Keywords

  • Transcranial Direct Current Stimulation
  • tDCS
  • Covid Persistente
04

In context

Post-Acute COVID-19 Syndrome Reclassified

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's planned enrollment of 87 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

Fundación Universidad Católica de Valencia San Vicente Mártir is the lead sponsor of 25 studies on the registry; 7 are open to participants now.

Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is COVID-19. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Persistent Covid
  • Men and women
  • All ages from 16 years old
  • Patients who passed the Covid in its acute phase in an asymptomatic, mild and severe way.

Exclusion criteria

Exclusion Criteria:

  • Patients without confirmation with positive PCR in the acute phase of Covid-19
  • Patients with Persistent Covid who do not have at least one of these symptoms: migraines, headaches, chronic pain, neuropathic pain, arthralgia, myalgias
  • Patients with pacemaker / defibrillator
  • Patients with brain implants
  • Patients with cranial fractures
  • Pregnant
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
87 participants (estimated)

Study arms

  • Placebo comparator
    Sham

    Same electrode montage as another arm; current ramped up and down, then switched off, to mimic the sensations of active stimulation.

    Device: Sham (No Treatment)

  • Experimental
    Anodal tDCS

    Original arm. Anode over M1/C3, cathode over Fp2

    Device: Transcranial Direct Current Therapy (tDCS)

  • Experimental
    Cathodal tDCS

    Cathode over M1/C3, anode over Fp2; same intensity, duration and number of sessions.

    Device: Transcranial Direct Current Therapy (tDCS)

  • Experimental
    Bifrontal tDCS

    Anode over F3, cathode over F4; same intensity, duration and number of sessions.

    Device: Transcranial Direct Current Therapy (tDCS)

Interventions

  • DeviceTranscranial Direct Current Therapy (tDCS)

    Transcranial direct therapy (tDCS) is a non-invasive neuromodulation therapy of the cerebral cortex, which consists of the application of electrical microcurrents, of approximately 2mA, through surface electrodes placed on the scalp. Transcranial therapy (tDCS) produces immediate effects on the ability of neurons to change their electrical potential. Each session lasts between 20 and 30 minutes, and approximately 20 consecutive sessions should be performed. It will be applied through two surface electrodes of 25 to 35 cm2 at 2 mA. The equipment has a European health certificate (CE), so it is an approved equipment that complies with all the safety measures for the application of the treatment.

  • DeviceSham (No Treatment)

    Same electrode montage as other arm; current ramped up and then down, then switched off, to mimic the sensations of active stimulation. Same session schedule as active arms.

07

What researchers measure

Primary outcomes

  1. CHANGE FROM PRE-TREATMENT DEGREE CHRONIC BODY PAIN AT INMEDIATE POST-TREATMENT, 1 MONTH, 3 MONTHS AND 6 MONTHS

    MEASURED WITH 2 SPECIFIC PAIN SCALES (EVA-Visual Analog SCALE AND MCGILL PAIN QUESTIONNAIRE). EVA SCALE (0 no pain-10 maximun pain). MCGILL QUESTIONNAIRE (0 no pain-66 maximun pain)

    Time frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS

  2. CHANGE FROM PRE-TREATMENT INTENSE MIGRAINES OR HEADACHES AT INMEDIATE POST-TREATMENT, 1 MONTH, 3 MONTHS AND 6 MONTHS

    MEASURED WITH 2 SPECIFIC SCALES (MIDAS-Migraine dissability Assessment SCALE AND HIT-6 QUESTIONNAIRE-headache impact test). MIDAS SCALE (0 nil disability - \>21 severe disability). HIT-6 QUESTIONNAIRE (0 no impact - \>60 very severe impact).

    Time frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS

Secondary outcomes

  1. CHANGE FROM PRE-TREATMENT QUALITY OF LIFE (SF-12 QUESTIONNAIRE) AT INMEDIATE POST-TREATMENT, 1 MONTH, 3 MONTHS AND 6 MONTHS

    MEASURED WITH 1 SPECIFIC SCALE (SF-12 QUESTIONNAIRE). (0 worst quality of life - 100 best quality of life)

    Time frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS

  2. CHANGE FROM PRE-TREATMENT MOOD AT INMEDIATE POST-TREATMENT, 1 MONTH, 3 MONTHS AND 6 MONTHS

    MEASURED WITH 1 SPECIFIC SCALE (EVEA-mood rating SCALE). (0 nothing - 10 a lot)

    Time frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS

  3. CHANGE FROM PRE-TREATMENT SLEEP QUALITY (SF-12 QUESTIONNAIRE) AT INMEDIATE POST-TREATMENT, 1 MONTH, 3 MONTHS AND 6 MONTHS

    MEASURED WITH 3 SPECIFIC SCALES (ISI-Insomnia Severity Index, Pittsburg Sleep Quality Index AND Epworth Sleepiness Scale). ISI (0-7 no insomnia, 8-14 subclinical insomnia, 15-21 moderated insomnia, 22-28 severe insomnia). PITTSBURG (0-4 good sleep quality, \> 5 sleep problems). EPWORTH (0-10 normal sleepiness, 11-14 mild daytime sleepiness, 15-18 moderate daytime sleepiness, 19-24 severe daytime sleepiness).

    Time frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS

  4. BRAIN RESILIENCE (EEG-TMS) AT PRE-TREATMENT AND INMEDIATE POST-TREATMENT

    EEG-TMS AND PPTMS PRE-TREATMENT AND INMEDIATE POST-TREATMENT

    Time frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT

08

Study locations

2 of 2 sites recruiting
  • Clínica Paiporta
    Paiporta, Valencia 46200, Spain
    Recruiting
  • Escuela de Doctorado. Universidad Católica de Valencia San Vicente Mártir. (Doctoral School. Catholic University of Valencia San Vicente Mártir)
    Valencia, Valencia 46001, Spain
    Recruiting
    • JORGE ALARCÓN JIMÉNEZ · Contactjorge.alarcon@ucv.es
    • LAURA GARCÍA MARTÍNEZ · Principal investigator
09

References and documents

Publications

  • Conde-Anton A, Hernando-Garijo I, Jimenez-Del-Barrio S, Mingo-Gomez MT, Medrano-de-la-Fuente R, Ceballos-Laita L. Effects of transcranial direct current stimulation and transcranial magnetic stimulation in patients with fibromyalgia. A systematic review. Neurologia (Engl Ed). 2020 Oct 15:S0213-4853(20)30278-4. doi: 10.1016/j.nrl.2020.07.024. Online ahead of print. English, Spanish. PubMed 33071017 ↗
  • Pacheco-Barrios K, Cardenas-Rojas A, Thibaut A, Costa B, Ferreira I, Caumo W, Fregni F. Methods and strategies of tDCS for the treatment of pain: current status and future directions. Expert Rev Med Devices. 2020 Sep;17(9):879-898. doi: 10.1080/17434440.2020.1816168. Epub 2020 Sep 15. PubMed 32845195 ↗

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Nov 2026, 43 months after the start.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 43 months is above that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jul 2023 → Nov 2026 and completion Jul 2023 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Mar 22, 2023
StartActual
Apr 1, 2023
Primary completionEst.
Nov 5, 2026was Jul 2023
CompletionEst.
Mar 1, 2027was Jul 2023
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Recruiting
changed Oct 15, 2026
Sites
1 site added, 1 site removed
Show site
  • Escuela de Doctorado. Universidad Católica de Valencia San Vicente Mártir. (Doctoral School. Catholic University of Valencia San Vicente Mártir) · Valencia, Spain
Show 1 removed
  • Escuela de Doctorado. Universidad Católica de Valencia San Vicente Mártir. (Doctoral School. Catholic University of Valencia San Vicente Mártir) · Valencia, Spain
Oct 15, 2026
Primary completion
Jul 2023→Nov 5, 2026
Oct 15, 2026
Study completion
Jul 2023→Mar 1, 2027
Oct 15, 2026
Enrollment
27→87
Oct 15, 2026
Interventions
Added Device: Sham (No Treatment). Arms added: Sham·Anodal tDCS·Cathodal tDCS·Bifrontal tDCS; arms removed: Treatment group
Oct 15, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedCHANGE FROM PRE-TREATMENT DEGREE CHRONIC BODY PAIN AT INMEDIATE POST-TREATMENT, 1 MONTH AND, 3 MONTHS AND 6 MONTHSTime frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS → PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
  • EditedCHANGE FROM PRE-TREATMENT INTENSE MIGRAINES OR HEADACHES AT INMEDIATE POST-TREATMENT, 1 MONTH AND, 3 MONTHS AND 6 MONTHSTime frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS → PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
Oct 15, 2026
Secondary outcomes
2 edited, 2 added
What changed in the outcomes
  • EditedCHANGE FROM PRE-TREATMENT QUALITY OF LIFE (SF-12 QUESTIONNAIRE) AT INMEDIATE POST-TREATMENT, 1 MONTH AND, 3 MONTHS AND 6 MONTHSTime frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS → PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
  • EditedCHANGE FROM PRE-TREATMENT MOOD AT INMEDIATE POST-TREATMENT, 1 MONTH AND, 3 MONTHS AND 6 MONTHSTime frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS → PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
  • AddedCHANGE FROM PRE-TREATMENT SLEEP QUALITY (SF-12 QUESTIONNAIRE) AT INMEDIATE POST-TREATMENT, 1 MONTH, 3 MONTHS AND 6 MONTHSTime frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
  • AddedBRAIN RESILIENCE (EEG-TMS) AT PRE-TREATMENT AND INMEDIATE POST-TREATMENTTime frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Status unknown→Recruiting
    1 site added, 1 site removed
    Show site
    • Escuela de Doctorado. Universidad Católica de Valencia San Vicente Mártir. (Doctoral School. Catholic University of Valencia San Vicente Mártir) · Valencia, Spain
    Show 1 removed
    • Escuela de Doctorado. Universidad Católica de Valencia San Vicente Mártir. (Doctoral School. Catholic University of Valencia San Vicente Mártir) · Valencia, Spain
    Primary completion Jul 2023→Nov 5, 2026
    Study completion Jul 2023→Mar 1, 2027
    Enrollment 27→87
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedCHANGE FROM PRE-TREATMENT DEGREE CHRONIC BODY PAIN AT INMEDIATE POST-TREATMENT, 1 MONTH AND, 3 MONTHS AND 6 MONTHSTime frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS → PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
    • EditedCHANGE FROM PRE-TREATMENT INTENSE MIGRAINES OR HEADACHES AT INMEDIATE POST-TREATMENT, 1 MONTH AND, 3 MONTHS AND 6 MONTHSTime frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS → PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
    Secondary outcomes 2 edited, 2 added
    What changed in the outcomes
    • EditedCHANGE FROM PRE-TREATMENT QUALITY OF LIFE (SF-12 QUESTIONNAIRE) AT INMEDIATE POST-TREATMENT, 1 MONTH AND, 3 MONTHS AND 6 MONTHSTime frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS → PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
    • EditedCHANGE FROM PRE-TREATMENT MOOD AT INMEDIATE POST-TREATMENT, 1 MONTH AND, 3 MONTHS AND 6 MONTHSTime frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS → PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
    • AddedCHANGE FROM PRE-TREATMENT SLEEP QUALITY (SF-12 QUESTIONNAIRE) AT INMEDIATE POST-TREATMENT, 1 MONTH, 3 MONTHS AND 6 MONTHSTime frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
    • AddedBRAIN RESILIENCE (EEG-TMS) AT PRE-TREATMENT AND INMEDIATE POST-TREATMENTTime frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT
    Interventions Added Device: Sham (No Treatment). Arms added: Sham·Anodal tDCS·Cathodal tDCS·Bifrontal tDCS; arms removed: Treatment group
    + 7 other changes: identifiers, verification date, responsible party, description, conditions, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05780450
Lead sponsor
Fundación Universidad Católica de Valencia San Vicente Mártir
Responsible party
Jorge Alarcón Jiménez (Professor, Fundación Universidad Católica de Valencia San Vicente Mártir) — Principal investigator
First posted
Mar 22, 2023
Start date
Apr 1, 2023
Primary completion
Nov 5, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

LAURA GARCÍA MARTÍNEZ
Contact
lauragarciamartinez@mail.ucv.es
+34691635330
LAURA GARCÍA MARTÍNEZ
principal investigator · Escuela de Doctorado. Universidad Católica de Valencia San Vicente Mártir. (Doctoral School. Catholic University of Valencia San Vicente Mártir)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion